Pharmaxis Ltd. (PXS.AX)
-ASX 0.23 
0.05(27.78%) May 24, 2:10AM EDT
| Prev Close: | 0.18 |
|---|
| Open: | 0.20 |
|---|
| Bid: | 0.23 |
|---|
| Ask: | 0.23 |
|---|
| 1y Target Est: | 0.35 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.20 - 0.24 |
|---|
| 52wk Range: | 0.12 - 1.42 |
|---|
| Volume: | 10,856,434 |
|---|
| Avg Vol (3m): | 2,693,810 |
|---|
| Market Cap: | 71.07M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- 15.04.2013 - Notice of change of interests of substantial holder - Montoyaat Reuters(Sun, Apr 14)
- 10.04.2013 - Pharmaxis Announces Bronchitol Distributor for Brazilat Reuters(Tue, Apr 9)
- 10.04.2013 - Investor Conference Call Details - 11 April 2013at Reuters(Tue, Apr 9)
- 02.04.2013 - Appendix 3Y - Richard van den Broekat Reuters(Mon, Apr 1)
- 12.03.2013 - Pharmaxis Appoints Gary Phillips as New Chief Executive Officerat Reuters(Mon, Mar 11)
- 04.02.2013 - Notice of initial substantial holder - Montoya Investmentsat Reuters(Sun, Feb 3)
- 29.01.2013 - Request for Trading Haltat Reuters(Mon, Jan 28)
- 13.11.2012 - Appendix 3B - Exercise of Employee Optionsat Reuters(Mon, Nov 12)
- 08.11.2012 - Appendix 3B - Exercise of Employee Optionsat Reuters(Wed, Nov 7)
- 30.10.2012 - Appendix 3B - Exercise of Employee Optionsat Reuters(Mon, Oct 29)
- Pharmaxis’s Bronchitol Wins U.K. Cost Agency's Backingat Bloomberg(Thu, Oct 25)
- 08.10.2012 - Conference Call Detailsat Reuters(Mon, Oct 8)
- 08.10.2012 - Response to ASX Price Queryat Reuters(Mon, Oct 8)
- Starpharma still reaching for the skyat Reuters(Thu, Aug 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 21.00 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.13 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 0.14 |
|---|
Business Summary
Pharmaxis Ltd, a pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory diseases in the United States, Europe, Australia, and southeast Asia.
View More